{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT06027073",
      "orgStudyIdInfo": {
        "id": "CM-01966"
      },
      "organization": {
        "fullName": "Medical University of Silesia",
        "class": "OTHER"
      },
      "briefTitle": "Biologics and Sublingual Immunotherapy",
      "officialTitle": "Adding Biological Therapy to Asthmatic Patients on Allergen Immunotherapy to House Dust Mites",
      "acronym": "BSIPL"
    },
    "statusModule": {
      "statusVerifiedDate": "2023-08",
      "overallStatus": "NOT_YET_RECRUITING",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2024-05-01",
        "type": "ESTIMATED"
      },
      "primaryCompletionDateStruct": {
        "date": "2026-10-01",
        "type": "ESTIMATED"
      },
      "completionDateStruct": {
        "date": "2028-03-01",
        "type": "ESTIMATED"
      },
      "studyFirstSubmitDate": "2023-08-30",
      "studyFirstSubmitQcDate": "2023-08-30",
      "studyFirstPostDateStruct": {
        "date": "2023-09-07",
        "type": "ACTUAL"
      },
      "lastUpdateSubmitDate": "2023-08-30",
      "lastUpdatePostDateStruct": {
        "date": "2023-09-07",
        "type": "ACTUAL"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "SPONSOR"
      },
      "leadSponsor": {
        "name": "Medical University of Silesia",
        "class": "OTHER"
      },
      "collaborators": [
        {
          "name": "Centrum Medyczne Andrzej Bożek",
          "class": "UNKNOWN"
        }
      ]
    },
    "oversightModule": {
      "oversightHasDmc": false,
      "isFdaRegulatedDrug": false,
      "isFdaRegulatedDevice": false
    },
    "descriptionModule": {
      "briefSummary": "Most current studies involve using a biological drug to increase the safety of allergen immunotherapy (AIT) especially in the treatment of food allergies, to avoid the risk of anaphylaxis. However, adding Xolair® to AIT may improve the therapy's effectiveness. There are still few observations on this topic, especially in patients with house dust mite (HDM)-driven asthma.",
      "detailedDescription": "Assess the effectiveness of combined therapy Actair® plus Xolair compared to monotherapy with Actair® or Xolair® or standard symptomatic therapy in patients with mild or moderate allergic asthma to HDM.\n\nTreatment duration: 24 months Follow-up duration:12 months Total duration: 36 months (not including screening and randomization period) May 2024 - March 2028 Consisting of a 4 to 5 months screening phase (with 1 month observation period prior to randomization) a treatment phase of 24 months and post-treatment follow-up phase 12 months"
    },
    "conditionsModule": {
      "conditions": [
        "Asthma, Allergic"
      ],
      "keywords": [
        "IgE",
        "asthma",
        "omalizumab",
        "immunotherapy"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "designInfo": {
        "allocation": "RANDOMIZED",
        "interventionModel": "PARALLEL",
        "interventionModelDescription": "The randomization procedure with random selection will rely on computer-generated numbers using a computer program (Excel, version 14.2.0, 2020 Microsoft Corporation). The patients will be randomized into four groups 1:1:1:1 as follows:\n\nGroup A: Xolair® Group B: Actair® Group C: Actair® and Xolair® Group D: Standard of Care (no interventional therapy).",
        "primaryPurpose": "TREATMENT",
        "maskingInfo": {
          "masking": "NONE"
        }
      },
      "enrollmentInfo": {
        "count": 150,
        "type": "ESTIMATED"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "omalizumab",
          "type": "ACTIVE_COMPARATOR",
          "description": "standard antiasthmatic therapy and omalizumab",
          "interventionNames": [
            "Biological: omalizumab"
          ]
        },
        {
          "label": "oral tablet HDM-immunotherapy",
          "type": "ACTIVE_COMPARATOR",
          "description": "standard antiasthmatic therapy and oral immunotherapy",
          "interventionNames": [
            "Biological: omalizumab"
          ]
        },
        {
          "label": "combi therapy",
          "type": "ACTIVE_COMPARATOR",
          "description": "standard antiasthmatic therapy and omalizumab, and oral immunotherapy",
          "interventionNames": [
            "Biological: omalizumab"
          ]
        },
        {
          "label": "control",
          "type": "NO_INTERVENTION"
        }
      ],
      "interventions": [
        {
          "type": "BIOLOGICAL",
          "name": "omalizumab",
          "description": "adding omalizumab to anti asthmatic therapy",
          "armGroupLabels": [
            "combi therapy",
            "omalizumab",
            "oral tablet HDM-immunotherapy"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Assess the effectiveness of combined therapy : omalizumab+ immunotherapy",
          "description": "Daily dose of inhaled steroids (changes)",
          "timeFrame": "3 years"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:• \\>18 years old\n\n* A total IgE between 30-700 IU/mL\n* Moderate asthma with perennial symptoms confirmed as HDM-driven asthma based on medical history and positive nasal provocation tests, partially controlled asthma;\n* FEV1 \\>70% at baseline;\n* Positive skin prick test results for D. pteronyssinus, D. farinae\n\nExclusion Criteria:\n\n* Sensitisation to other allergens with clinical signs not related to HDM\n* Uncontrolled asthma,\n* Other serious diseases or chronic unstable diseases\n* Allergen immunotherapy during the past 5 years\n* Contraindicating allergen immunotherapy and omalizumab treatment.",
      "healthyVolunteers": false,
      "sex": "ALL",
      "minimumAge": "18 Years",
      "maximumAge": "65 Years",
      "stdAges": [
        "ADULT",
        "OLDER_ADULT"
      ]
    },
    "contactsLocationsModule": {
      "centralContacts": [
        {
          "name": "Andrzej Bozek, prof",
          "role": "CONTACT",
          "phone": "0048608318547",
          "email": "andrzejbozek@o2.pl"
        }
      ]
    },
    "referencesModule": {
      "references": [
        {
          "pmid": "39363801",
          "type": "DERIVED",
          "citation": "Batard T, Taille C, Guilleminault L, Bozek A, Floch VB, Pfaar O, Canonica WG, Akdis C, Shamji MH, Mascarell L. Allergen Immunotherapy for the Prevention and Treatment of Asthma. Clin Exp Allergy. 2025 Feb;55(2):111-141. doi: 10.1111/cea.14575. Epub 2024 Oct 4."
        }
      ]
    },
    "ipdSharingStatementModule": {
      "ipdSharing": "NO",
      "description": "by computer database registration"
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2026-02-04"
    },
    "conditionBrowseModule": {
      "meshes": [
        {
          "id": "D001249",
          "term": "Asthma"
        }
      ],
      "ancestors": [
        {
          "id": "D001982",
          "term": "Bronchial Diseases"
        },
        {
          "id": "D012140",
          "term": "Respiratory Tract Diseases"
        },
        {
          "id": "D008173",
          "term": "Lung Diseases, Obstructive"
        },
        {
          "id": "D008171",
          "term": "Lung Diseases"
        },
        {
          "id": "D012130",
          "term": "Respiratory Hypersensitivity"
        },
        {
          "id": "D006969",
          "term": "Hypersensitivity, Immediate"
        },
        {
          "id": "D006967",
          "term": "Hypersensitivity"
        },
        {
          "id": "D007154",
          "term": "Immune System Diseases"
        }
      ]
    },
    "interventionBrowseModule": {
      "meshes": [
        {
          "id": "D000069444",
          "term": "Omalizumab"
        }
      ],
      "ancestors": [
        {
          "id": "D000888",
          "term": "Antibodies, Anti-Idiotypic"
        },
        {
          "id": "D000906",
          "term": "Antibodies"
        },
        {
          "id": "D007136",
          "term": "Immunoglobulins"
        },
        {
          "id": "D007162",
          "term": "Immunoproteins"
        },
        {
          "id": "D001798",
          "term": "Blood Proteins"
        },
        {
          "id": "D011506",
          "term": "Proteins"
        },
        {
          "id": "D000602",
          "term": "Amino Acids, Peptides, and Proteins"
        },
        {
          "id": "D061067",
          "term": "Antibodies, Monoclonal, Humanized"
        },
        {
          "id": "D000911",
          "term": "Antibodies, Monoclonal"
        },
        {
          "id": "D012712",
          "term": "Serum Globulins"
        },
        {
          "id": "D005916",
          "term": "Globulins"
        }
      ]
    }
  },
  "hasResults": false
}